Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571)

Trial Profile

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Imatinib (Primary) ; Cytarabine; Interferon alpha
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results from this and other five studies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 24 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
    • 24 Aug 2013 New source identified and integrated (M.D. Anderson Cancer Center; ID01-015).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top